Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline in 2024, with several candidates entering late ...

such as Boehringer Ingelheim and Pfizer, that are awaiting review of submitted applications for interchangeability designation for their approved biosimilars. Introduction of Policies Encouraging ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

We approached them in the middle of last year and things moved fairly quickly,” says Andrew Curtis, biosimilar and orphan drugs director for Pfizer's established products business.

Revenues from oncology biosimilars were $285 million, down 7% year over year. Pfizer raised its revenue and earnings guidance for 2024 for the second time this year. Adjusted earnings are expected ...

The NHS saved nearly £99.4 million by using Infliximab, the biosimilar version of Jannssen’s Remicade and £60 million by switching from Amgen/Pfizer’s Enbrel to Etanercept. In addition two ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... concerns include competition from generic drugs and biosimilars and the looming patent cliff, with over $300 billion ...